Melatonin and human cardiovascular disease

PANDI-PERUMAL SR; AKINSEYE OA; DHANDAPANY PS; BAHAMMAM AS; KENDZERSKA T; OJIKE NI; BROWN GM; BUTTOO K; CARDINALI DP

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

SAGE PUBLICATIONS INC

Lugar: Thousand Oaks, California.; Año: 2017 vol. 22 p. 122 - 132

1074-2484

The possible therapeutic role ofmelatonin in the pathophysiology of coronary artery disorder (CAD) isincreasingly being recognized. In humans, exogenous melatonin has been shown todecrease nocturnal hypertension, improve systolic and diastolic blood pressure,reduce the pulsatility index in the internal carotid artery, decrease plateletaggregation, and reduce serum catecholamine levels. Low circulating levels of melatoninare reported in individuals with CAD, arterial hypertension, and congestiveheart failure. This review assesses current literature on the cardiovasculareffects of melatonin in humans. It can be concluded that melatonin deserves tobe considered in clinical trials evaluating novel therapeutic interventions forcardiovascular disorders.